natgillin/translations-raw huggingface dataset:
wherein X is independently selected from halogens; at a temperature of about 30 to about 60 degrees Celsius for a period of about 12 to about 18 hours at a pH from about 7 to about 9; subsequently concentrating the aqueous reaction mixture such that precipitates of pyrophosphates do not form; 
(VI) pri čemu svaki R' i R* je neovisno odabran od NH,, te supstituiranih ili nesupstituiranih alifatskih amina, pri čemu R? je odabran od supstituiranih ili nesupstituiranih alifatskih amina; te pri čemu X je neovisno odabran od halogena; kod temperature od oko 30 do oko 60 stupnjeva Celzija kroz period vremena od oko 12 do oko 18 sati kod pH od oko 7 do oko 9; (ii) naknadno koncentriranje vodene reakcijske smjese tako da se ne odvija taloženje pirofosfata;
The pharmaceutical composition of claim 1 or 2, wherein said second binding domain specific for human CEA comprises at least the amino acid sequence "DRGLRFYFDY" (SEQ ID NO. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedena druga vežuća domena specifična za ljudski CEA u najmanju ruku sadrži aminokiselinski slijed "DRGLRFYFDY" (SEQ ID NO.
A second process comprises reacting a sub-stoichiometric amount of a mineral cobalt compound, preferably cobalt hydroxide, with an unsaturated polymeric fatty acid, whereafter further polymerisation is performed with polyols until a mean molecular weight of more than 3000 is obtained. 
- reakcija mineralnog spoja kobalta u količini manjoj od stehiometrijske, poželjno kobaltova hidroksida, s nezasićenom polimernom masnom kiselinom, nakon čega se daljnja polimerizacija provodi s poliolima dok se ne postigne prosječna molekulska masa veća od 3000;
The method according to claim 3, wherein the disease is selected from the group consisting of itch, irritable bowel diseases, cold-induced and/or exhacerbated respiratory disorders, ischemia, pain, urological disorders, stroke, psychiatric disorders and neurodegeneration. 
Spoj kako je definiran u bilo kojem od patentnih zahtjeva 1 do 13, naznačen time što je namijenjen upotrebi za prevenciju i/ili liječenje bolesti odabrane iz skupine koju čine svrbež, iritabilne bolesti crijeva, prehladom izazvani i/ili pogoršani respiratorni poremećaji, ishemija, bol, urološki poremećaji, moždani udar, psihijatrijski poremećaji i neurodegeneracija.
allocate the third frequency resource for transmission of an uplink data signal in the middle of the operating bandwidth, wherein the CQI signal is transmitted periodically, and the acknowledgement signal is transmitted in response to transmission of a downlink data signal. 
dodjeljivanje drugog frekvencijskog resursa za prijenos signala potvrde između prvog frekvencijskog resursa i trećeg frekvencijskog resursa u operativnoj pojasnoj širini; i dodjeljivanje trećeg frekvencijskog resursa za prijenos uzlazne veze podatkovnog signala u sredinu operativne pojasne širine, naznačeno time da se CQI signal prenosi periodično, i signal potvrde se prenosi u odgovoru na prijenos silazne veze podatkovnog signala.
The method of claim 1, wherein the compound of formula II is according to formula (30): 
Spoj iz patentnog zahtjeva 1 u skladu sa formulom 30:;
A composition according to claim 10, wherein at least one of the one or more isolated monomeric platinum complexes is (Trans-1,2-cyclohexanediamine)-trans-dihyroxo(dihydrogen pyrophosphato)platinum(IV). 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 23, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV).
In certain examples of the disclosure theneuropsychiatric disorder is schizophrenia and/or bipolar disorder, and the neuropharmaceutical is an antipsychotic drug (e.g., butyrophenone, phenothiazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, levomepromazine, promethazine, thioxanthene, chlorprothixene, flupenthixol, thiothixene, zuclopenthixol, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, paliperidone, aripiprazole, a dopamine partial agonist, lamotrigine, memantine, tetrabenazine, cannabidiol, and/or LY2140023). 
Sastav za korištenje u skladu sa zahtjevom 1., gdje se navedeni antipsihotik bira iz skupine koja uključuje butirofenon, fenotiazin, flufenazin, perfenazin, proklorperazin, tioridazin, trifluoperazin, mezoridazin, promazin, triflupromazin, levomepromazin, prometazin, tioksanten, klorprotiksen, flupentiksol, tiotiksen, zuklopentiksol, klozapin, olanzapin, risperidon, kvetiapin, ziprasidon, amisulprid, azenapin, paliperidon, aripiprazol, djelomični agonist dopamina (BIFEPRUNOX&, NORCLOZAPINE&(ACP-104)), lamotrigin, memantin, tetrabenazin, kanabidiol, L.Y2140023, Droperidol, Pimozid, Butaperazin, Karfenazin, Remoksiprid, Piperacetazin, Sulpirid, akamprosat i tetrabenazin (XENAZINE&, NITOMAN &).
The method according to claim 18, characterized in that an additional component in liquid form is incorporated to the mixture in solid form obtained previously in step 5) using a combination of precipitated amorphous silica and starch as a vehicle. 
Postupak prema patentnom zahtjevu 17, naznačen time da je dodatna komponenta u tekućem obliku uključena u smjesu u krutom obliku dobivenom ranije u koraku 5) uz pomoć kombinacije precipitiranog amorfnog silicija i škroba kao nosača.
The compound according to claim 6, which is: and the pharmaceutically acceptable salts thereof. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da je to: i njegove farmaceutski prihvatljive soli.
providing a dialkyl(halomethyl)phosphate; reacting an N atom of the piperazine group with the dialkyl(halomeihyl)phosphate to obtain a quaternary ammonium methylene phosphate compound, 
reakciju N atoma piperazinske grupe sa dialkil(halometil)fosfatom, kako bi se dobio spoj kvaternerni amonijev metilen fosfat, pri čemu se navedeni postupak sprovodi da se dobije spoj GA1, u skladu sa zahtjevom 1.
A sampler for taking a sample from a body cavity comprising a tubular means adapted to be introduced in said cavity, a storage means connected to said tubular means and a vacuum means connected to said storage means and/or said tubular means; said tubular means comprising a rigid tube having a smooth outer surface and a diameter of at least 1 cm and a curved introduction end, wherein said rigid tube in operation provides a closure in the body cavity for a flushing solution when expelled; said sampler further comprising a number of sampling openings wherein said sample opening are positioned only at the curved introduction end of said tubular means, wherein said number of sampling openings comprises a central opening having a diameter of less than 5 mm; said sampler further comprising a liquid containing means and a pump means to expel said flushing solution from said liquid containing means through said curved introduction end of said rigid tube. 
Naprava za uzimanje uzorka (1, 11,31, 41) iz tjelesne šupljine, takvog uzorka kao što su uzorci iz grlića maternice, koja naprava obuhvaća sredstvo koje ima oblik cijevi (4, 14, 34, 44) 1 koje sredstvo se uvodi u navedenu šupljinu, pri čemu je krajnji dio sredstva koje se uvodi (8, 18, 38, 48) zaobljen i on određuje središnji otvor za uzimanje uzorka (6, 16, 36, 46), sredstvo za pohranjivanje koje je spojeno na navedeno sredstvo koje ima oblik cijevi 1 sredstvo za stvaranje vakuuma koje je spojeno na navedeno sredstvo za pohranjivanje i/ili na sredstvo koje ima oblik cijevi, naznačena time što sredstvo koje ima oblik cijevi ima krutu cijev koja ima promjer od najmanje 1 cm, i što je samo na zaobljenom krajnjem dijelu koji se uvodi predviđen stanoviti broj otvora za uzimanje uzorka, koji otvori imaju promjer manji od 5 mm.
The person skilled in the art will understand that release of the active ingredient or of component (c) and/or (d) from the particular subunit may be controlled by the thickness of the separation layer. 
Stručnjak razumije, da se također pomoću debljine razdjelnog sloja može upravljati oslobađanjem djelatne tvari, odnosno komponente (c) i/ili (d) iz dotične podjedinice.
An antibody of any one of claims 1-7 and/or a conjugate of claim 8 for use in a method of (i) inhibiting growth of a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface, (ii) killing a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface, or (iii) inhibiting metastatic spread of a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface. 
Antitijelo suglasno bilo kojem od zahtjeva 1-11 i/ili neki konjugat suglasno zahtjevu 12, za primjenu u postupku (i) inhibicije rasta kancerske stanice koja eksprimira CLDN6 i koja je naznačena asocijacijom CLDN6 na membrani stanice i (ii) ubijanja kancerske stanice koja eksprimira CLDN6 i koja je naznačena asocijacijom CLDN6 na svojoj staničnoj membrani, ili (iii) inhibicije metastatičkog širenja kancerske stanice koja eksprimira CLDN6 i koja je naznačena asocijacijom CLDN6 na svojoj staničnoj membrani.
The method of claim 1, wherein the slurry has an initial temperature of about 90-150° F. (32-66° C.). 
Metoda u skladu sa patentnim zahtjevom 1, gdje kaša ima početnu temperaturu od oko 90-150"F (32-66*C).
Briefly, twenty-five day old male Spraque-Dawley rats are administered an GnRH antagonist in saline or other suitable formulation by oral gavage, subcutaneous injection, or intravenous injection. 
Ukratko, na 25 dana starim mužjacima Spraque-Dawley štakora primijenjen je antagonist GnRH u fiziološkoj otopini ili u kojoj drugoj pogodnoj formulaciji, oralnim putem, supkutanom injekcijom ili intravenskom injekcijom.
The use of claim 5, wherein said pharmaceutically acceptable carrier comprises lotions, creams, gels, emulsions, or sprays. 
Uporaba prema zahtjevu 5, naznačena time da navedeni farmaceutski prihvatljiv nosač sadrži losione, kreme, gelove, emulzije ili sprejeve.
The user equipment according to claim 6, further comprising a canceling module, configured to after the sending module sends the first power headroom report, be triggered by the sending module to cancel the first power headroom report that has been triggered. 
Korisnička oprema prema zahtjevu 6, naznačena time da dodatno sadrži modul za poništavanje, podešen da nakon što modul za slanje pošalje prvo izvješće o zadržanoj snazi, koji se aktivira sa modulom za slanje radi poništavanja prvog pokrenutog izvješća o zadržanoj snazi.
Lock according to claim 1, further comprising a guide lever (15) partially coming out of said body (11) . 
Brava u skladu s patentnim zahtjevom 1, naznačena time što dodatno ima navodeću polugu (15), koja djelomično izlazi iz navedenog tijela (11).
Y is a covalent bond, -CH2-O-CH2-, C1-C6 alkylenyl or C3-C7 cycloalkylenyl; a tautomer thereof or a pharmaceutically acceptable salt, or solvate of said compound or tautomer. 
Y je kovalentna veza, -CH2-O-CH>-, C,-Cs alkilenil ili Ca-C; cikloalkilenil; njegov tautomer ili farmaceutski prihvatljiva sol, ili solvat navedenog spoja ili tautomera,
Use according to any one of the preceding claims, wherein the fatty alcohol or fatty acid is selected from C12 to C36 aliphatic alcohols or acids, preferably stearyl alcohol, cetyl alcohol, cetostearyl alcohol, stearic acid, palmitic acid and mixtures thereof. 
Uporaba prema bilo kojem od prethodnih zahtjeva, gdje se masni alkohol ili masna kiselina izabiru iz skupine koja obuhvaća stearilni alkohol, cetilni alkohol, cetostearilni alkohol, stearinsku kiselinu, palmitinsku kiselinu i njihove smjese.
A lipid compound according to claim 1, wherein R2 and R3 are independently selected from a hydrogen atom or an ethyl group; or R2 and R3 are connected to form a cyclobutane group. 
Lipidni pripravak prema zahtjevu 1, naznačen time da R> i R3 su neovisno odabrani od vodikovog atoma ili etilne skupine; ili R» i Rs su spojeni tako da tvore ciklobutansku skupinu.
A method of decoding a video, the method comprising: receiving a bitstream of an encoded video; extracting, from the bitstream, information about a maximum size of a coding unit which is a data unit in which a picture is decoded, information about a maximum depth indicating a total number of possible times a maximum coding unit is split, and information about a coded depth and an encoding mode for coding units of the picture; 
- < ekstraktor (220) podešen tako, da iz toka bitova izvlači informaciju o maksimalnoj veličini kodirajuće jedinice, koja je jedinica podataka u kojoj je kodirana slika, informaciju o maksimalnoj dubini, koja označava ukupni broj mogućih dijeljenja maksimalne kodirajuće jedinice i informaciju o dubini kodiranja i načinu kodiranja jedinica slike;
Tetrakis(triphenylphosphine)palladium (2.9 g, 2.5 mmol) was added, the tube was sealed and the resulting mixture was heated with stirring at 90° C. overnight. After cooling to ambient temperature, the precipitate was removed by filtration. 
Doda se tetrakis(trifenilfosfin)paladij (2,9 g, 2,5 mmol), epruvetu hermetički zatvori, a dobivenu smjesu grije, uz miješanje, preko noći na 90 *C. Nakon hlađenja na tempcraturu okoliša talog se ukloni filtriranjem.
The invention also concerns a process for the manufacture of a nutritional composition according to the invention comprising preparing an aqueous phase comprising protein and digestible carbohydrates and preparing a fat phase comprising lipids, wherein phospholipids are present in the aqueous and/or fat phase, wherein the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, wherein the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 30 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, mixing the fat and aqueous phase and homogenizing the mixture of fat and aqueous phase into an oil-in-water emulsion with lipid globules at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid. 
HR P20161271 T1 PATENTNI ZAHTJEVI 1. Nutritivni pripravak koji sadrži ugljikohidrate, proteine i lipide, gdje su lipidi prisutni u obliku lipidnih globula, pri čemu i) sastav masnih kiselina unutar lipida obuhvaća linolensku kiselinu i alfa-linolensku kiselinu u težinskom omjeru od 2 do 10, ii) sastav masnih kiselina unutar lipida obuhvaća barem 10 tež.% palmitinske kiseline u odnosu na ukupne masne kiseline, i barem 30 tež.% te ukupne palmitinske kiseline je esterificirano na sn-2 položaju triglicerida iii) lipidne globule su barem djelomično obložene fosfolipidima na površini, količina fosfolipida prisutnih u nutritivnom pripravku je od 0.5 do 20 tež.% fosfolipida u odnosu na ukupne lipide, gdje nutritivni pripravak nije humano mlijeko.
The saccharide according to claim 9 wherein at least 10% of the Z groups are blocking groups and/or n is an integer from 15 to 25. 
Saharid u skladu s patentnim zahtjevom 9, naznačen time što su najmanje 10% skupina Z blokirajuće skupine i/ili n je cijeli broj od 15 do 25.
A composition comprising degarelix for use in the treatment of prostate cancer in a subject identified as having a cholesterol level ≥ 4 mmol/L. 
Sastav koji sadrži degareliks za upotrebu u liječenju karcinoma prostate kod subjekta identificiranog kao rizičnog za kardiovaskularnu bolest.
A method of modifying a boat so as to enable remote control of the boat, the boat having a manual control having an output connected to operate an electronic control, characterized by connecting an output of a receiver to a same electronic control which is operable by said manual control, the receiver being adapted to receive wireless signals from a hand-held transmitter, wherein the connecting step is performed without disturbing a connection between the manual control and the electronic control, wherein a signal generated by the receiver acts in parallel with a signal from said manual control. 
Metoda modifikacije plovila kojom se omogućava daljinsko upravljanje plovilom, plovilo ima manualnu upravljačku kontrolu koja ima izlaz spojen tako da upravlja elektroničkom upravljačkom kontrolom, naznačen time da se izlaz prijemnika spaja na istu elektroničku kontrolu koja se može upravljati sa spomenutom ručnom upravljačkom kontrolom, prijemnik je prilagođen tako da prima bežične signale sa ručnog odašiljača, pri čemu je postupak spajanja izveden tako da ne poremeti spoj između manualne i elektroničke upravljačke kontrole, pri čemu signal kojeg šalje odašiljač djeluje paralelno signalu sa spomenute ručne kontrole.
The immunogenic composition of any one of paragraphs 62-67 wherein the at least two further bacterial saccharide conjugates comprise a S. pneumoniae capsular saccharide derived from a strain selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije S. pneumoniae kojeg se dobiva iz soja kojeg se bira iz skupine koju čine serotipovi 1, 2, 3, 4, 5, 6A, 6B, TF, 8, 9N, 9V, 10A, IA, 12F, 14, 15B, I7F, 18C, 19A, 19F, 20, 22F, 23F 133F.
The pharmaceutical composition or package for use according to claim 13, wherein the amount of rasagiline or a pharmaceutically acceptable salt thereof is 2mg/day. 
Farmaceutski sastav ili pakiranje za uporabu u skladu s patentnim zahtjevom 13, naznačeni time, da količina rasagilina ili njegove farmaceutski prihvatljive soli jest 2 mg/dnevno.
Example 19. A device according to any of the preceding examples, wherein an outer diameter near said distal end (7) of said tubular member (4) is between 5-20 mm, such as 10-15 mm, such as 7-8 mm. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, kod kojega je vanjski promjer uz navedeni udaljeniji kraj (7) navedenog cijevnog elementa (4) između 5 - 20 mm, naročito takav da je 10 - 15 mm, odnosno takav da je 7-& mm.
The cap may have a generally planar top surface and at least one sidewall. 
Poklopac može imati općenito planarnu gornju površinu i najmanje jednu bočnu stijenku.
An antibody that is specific against the MHC/peptide complex of MHC with a peptide selected from the group consisting of SEQ ID No. 4 and 5. 
Antitijelo koje je specifično protiv MHC/peptidnog kompleksa MHC-a s peptidom koji se sastoji od SEQ ID br. 1. Komplet koji sadrži:
A compound of formula (I) or a physiologically acceptable solvate thereof as defined in claim 1 or claim 2, for use in veterinary or human medicine. 
Spoj formule (I), ili njegov fiziološki prihvatljiv solvat, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u veterini ili madicini.
As shown in the illustrated embodiments, the heat conducting member preferably contacts or overlaps a portion of the fuel element and the aerosol generating means, and may form the container which encloses the aerosol forming substance. 
Član za provođenje topline poželjno kontaktira ili preklapa dio gorivog elementa i sredstva za generiranje aerosola, 1 može formirati kontejner koji uklapa supstancu koja formira aerosol.
The pharmaceutical composition according to claim 3 wherein the pharmaceutically acceptable salt of glycopyrrolate is 3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. 
Ko-suspenzija u skladu s patentnim zahtjevom 8, naznačena time što je farmaceutski prihvatljiva sol glikopirolata 3-[(ciklopentilhidroksifenilacetiljoksi|-1,1-dimetilpirolidinijev bromid.
or a pharmaceutically acceptable salt thereof. 
T ili farmaceutski prihvatljiva sol tog spoja.
Pursuant to the invention, the coating composition is preferably and most easily and economically applied to the exterior surfaces of selected fruits and vegetables by application of a dilute liquid emulsion. 
Suglasno izumu, oblagajuća kompozicija se poželjno, najlakše i najekonomičnije primjenjuje na vanjske površine izabranog voća i povrća primjenom razrijeđenih tekućih emulzija.
or both R34 taken together with the atom to which they are both attached form a monocyclic C3-8cycloalkyl or monocyclic 3-8 membered heterocyclyl; RC is hydrogen or C1-6alkyl; and 
C,.shaloalkil, C3.g cikloalkil, ili 3-10-člani heterociklil; ili oba R* uzeta zajedno s atomom za koji su oba vezana tvore monociklični C_g cikloalkil ili monociklični 38-člani heterociklil;
The treatment of a traumatic brain injury can be monitored by employing a variety of neurological measurements. 
(54) Naziv izuma: REŽIM DOZIRANJA U LIJEČENJU TRAUMATSKE OZLJEDE MOZGA PROGESTERONOM
administering said composition to the eye of the mammal repeatedly for an extend period of time. The composition as in claim 23 wherein the composition is administered at least once a day for a period of at least one month. 
davanje navedenog pripravka u oko sisavca opetovano tijekom duljeg vremenskog razdoblja, pri čemu se poželjno pripravak primjenjuje najmanje jednom dnevno tijekom perioda od najmanje jednog mjeseca.
The CDR regions has been deleted for clarity. 
CDR regije su izbrisana radi jasnoće.
or else to an imination reaction with benzophenoneimine, followed by an acid hydrolysis and by a sulphonylation reaction with a sulphonyl chloride of formula R6SO2Cl, 
ili drugačije reakciji iminacije s benzofenoniminom, nakon čega slijedi kisela hidroliza i reakciji sulfonilacije sa sulfonil kloridom s formulom R6SO2Cl,
The method according to claim 1, wherein following addition of 2-((1-methylpropyl)amino)ethanol to the suspension, the suspension is introduced in a unit equipped with a conductivity-based regulation device. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da se, nakon dodavanja navedenog 2-((1-metilpropil)aminojetanola u navedenu otopinu, otopina dodaje u jedinicu opremljenu napravom za regulaciju na temelju vodljivosti.
assembling the contact part with the carrier part using first fixing means; and fixing the carrier part to the pick-up frame using second fixing means. 
dobivanje potpornog dijela (8) sklapanjem kontaktnog dijela (30) sa spojnim nosivim dijelom (28) korištenjem prvih sredstava za učvršćivanje (36, 42); te je naznačen time da sadrži
Manufacturing procedure according to claim 4, characterised in that part of the skirt (3) is also cut. 
Postupak proizvodnje sukladno Zahtjevu 1, naznačen time što je dio oplošja (3) također rezan.
It is possible to alter the order of the various reductive amination, alkylation, bromination and Suzuki condensation steps to give compounds of the present invention. 
Prilikom dobivanja spojeva prema ovom izumu moguće je izmijeniti redoslijed različitih koraka reduktivnog aminiranja, alkiliranja, bromiranja i Suzukijeve kondenzacije.
Further on, the device comprises at least two thermoblocks which can be brought selectively in fluid connection with the at least one water reservoir. 
Nadalje, ova naprava sadrži najmanje dva termobloka koje se može selektivno dovesti u fluidni kontakt s najmanje jednim spremnikom za vodu.
As used herein, “BTDS” means “Buprenorphine Transdermal System”, and “BTDS X”, wherein “X” is a number higher than zero, means a transdermal dosage form containing X milligrams of buprenorphine. 
"BTDS X"), pri čemu je "X" broj veći od nule, označuje transdermalni oblik doziranja koji sadrži X miligrama buprenorfina.
A component selected from the group consisting of: 
Komponenta odabrana iz skupine koju čine: